Log in

Relevant bibliographies by topics / Oligoasthenozoospermie / Journal articles

To see the other types of publications on this topic, follow the link: Oligoasthenozoospermie.

Journal articles on the topic 'Oligoasthenozoospermie'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Oligoasthenozoospermie.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Fischl, F., and J. Deutinger. "Die intrauterine homologe Insemination als Behandlungsversuch bei Oligo- und Oligoasthenozoospermie." Geburtshilfe und Frauenheilkunde 45, no. 09 (September 1985): 670–73. http://dx.doi.org/10.1055/s-2008-1036389.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Shaymaa Jawad Abdulrahman, Ibtisam A. AL-Ali, Thikra Abd Aun Hassan, and Ammar Mohammed Qassim. "Correlation of nerve growth factor with antioxidants and sperm parameters among Iraqi infertile males." International Journal of Research in Pharmaceutical Sciences 10, no. 2 (April 15, 2019): 1307–13. http://dx.doi.org/10.26452/ijrps.v10i2.531.

Full text

Abstract:

The level of nerve growth factor (NGF) in the blood and seminal plasma of asthenozoospermia and oligoasthenozoospermia patients were compared to normozoospermic males and the relationship between NGF with sperm parameters and seminal antioxidant capacity were estimated to determine the role of NGF in the etiology of male infertility. Eighty-one infertile males and 40 normospermic control subjects were included in this stud. NGF levels were measured in the blood and seminal plasma, and its correlation with total antioxidant capacity (TAC), catalase (CAT) and glutathione (GSH) levels and sperm parameters were studied. There was a general trend of decreased in serum and seminal NGF concentrations of asthenozoospermic and oligoasthenozoospermic when compared to the normozoospermic samples. There was no significant association between NGF and seminal antioxidant status in asthenozoospermia and oligoasthenozoospermia males. Nevertheless, CAT positively correlated with sperm concentration, total sperm motility, and normal sperm morphology but only showed a statistically significant correlation to total sperm motility in asthenozoospermic males. A strong positive association was detected between seminal plasma TAC activity and total sperm motility in both asthenozoospermic and oligoasthenozoospermia males. A decrease NGF levels in serum and seminal plasma could have a significant role in the etiology of impaired sperm functions.

APA, Harvard, Vancouver, ISO, and other styles

3

Yang, Zhuo, Xi Zhang, Zhimin Chen, and Changjiang Hu. "Effect of Wuzi Yanzong on Reproductive Hormones and TGF-β1/Smads Signal Pathway in Rats with Oligoasthenozoospermia." Evidence-Based Complementary and Alternative Medicine 2019 (April 16, 2019): 1–13. http://dx.doi.org/10.1155/2019/7628125.

Full text

Abstract:

Introduction. Wuzi Yanzong (WZYZ) formula, a famous traditional Chinese medicinal prescription, has been widely used to treat kidney essence insufficiency-induced oligoasthenozoospermia in ancient and modern clinical practice. Previous studies have demonstrated that WZYZ formula exhibits significantly therapeutic activity. The aim of this study was to evaluate the effect of WZYZ formula on the reproductive hormone levels and the TGF-β1/Smads signal pathway in the testis, to explore the underlying mechanisms of WZYZ formula to improve spermatogenic function of testis in rats with oligoasthenozoospermia. Materials and Methods. In order to control the quality of the drug, the main components of the WZYZ formula were analyzed by HPLC. A rat model of oligoasthenozoospermia was established, by daily administration of tripterygium glucosides for 4 weeks, and treated with 1.62g/kg of WZYZ formula. The testes were histopathologically examined and serum levels of gonadotropin release hormone (GnRH), estradiol (E2), follicle-stimulating hormone (FSH), testosterone (T), and luteinizing hormone (LH) were measured by ELISA. TGf-β1, Smad2, and Smad4 mRNA and protein levels in the testis were evaluated by immunohistochemistry (IHC), quantitative real-time RT-PCR (qRT-PCR), and Western blotting (WB). Result. Oral administration of WZYZ formula restored testicular structure and significantly increased the histology score in the oligoasthenozoospermic rats. In addition, WZYZ also significantly increased the serum levels of GnRH, LH, E2, and T and decreased that of FSH. Meanwhile, TGf-β1, Smad2, and Sma4 expression levels were significantly decreased. Conclusions. WZYZ alleviates oligoasthenozoospermia by restoring the reproductive hormones and targeting the TGf-β1/Smads pathway.

APA, Harvard, Vancouver, ISO, and other styles

4

Chen, Yangdi, Fanggang Bi, and Zixue Sun. "A network pharmacology approach to determine the underlying mechanisms of action of Yishen Tongluo formula for the treatment of oligoasthenozoospermia." PLOS ONE 16, no. 6 (June 21, 2021): e0252906. http://dx.doi.org/10.1371/journal.pone.0252906.

Full text

Abstract:

Oligoasthenozoospermia is a complex disease caused by a variety of factors, and its incidence is increasing yearly worldwide. Yishen Tongluo formula (YSTLF), created by Professor Sun Zixue, has been used to treat oligoasthenozoospermia in clinical practice for several decades with a good therapeutic effect. However, the chemical and pharmacological profiles of YSTLF remain unclear and need to be elucidated. In this study, a network pharmacology approach was applied to explore the potential mechanisms of YSTLF in oligoasthenozoospermia treatment. All of the compounds in YSTLF were retrieved from the corresponding databases, and the bioactive ingredients were screened according to their oral bioavailability (OB) and drug-likeness (DL). The potential proteins of YSTLF were obtained from the traditional Chinese medicine systems pharmacology (TCMSP) database and the Bioinformatics Analysis Tool for Molecular Mechanism of Traditional Chinese Medicine (BATMAN-TCM) database, while the potential genes of oligoasthenozoospermia were obtained from the GeneCards database and the DisGeNET database. The STRING database was used to construct an interaction network according to the common targets identified by the online tool Venny for YSTLF and oligoasthenozoospermia. The topological characteristics of nodes were visualized and analyzed through Cytoscape. Biological functions and significant pathways were determined and analyzed using the Gene Ontology (GO) knowledgebase, the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Metascape. Finally, the disease-formula-compound-target-pathway network was constructed by Cytoscape. A total of 106 bioactive ingredients and 134 potential targets from YSTLF were associated with oligoasthenozoospermia or considered to be therapeutically relevant. Pathway analysis indicated that the PI3K/Akt, MAPK and apoptosis signaling pathways were significant pathways involved in oligoasthenozoospermia. In conclusion, the current study expounded the pharmacological actions and molecular mechanisms of YSTLF in treating oligoasthenozoospermia from a holistic viewpoint. The potential molecular mechanisms were closely related to antioxidative stress, antiapoptosis and anti-inflammation, with TNF, CCND1, ESR1, NFKBIA, NR3C1, MAPK8, and IL6 being possible targets. This network pharmacology prediction may offer a helpful tool to illustrate the molecular mechanisms of the Chinese herbal compound YSTLF in oligoasthenozoospermia treatment.

APA, Harvard, Vancouver, ISO, and other styles

5

Hu, Mingrui, Yuanyuan Zhong, Wei Xiao, Yang Wang, Tao Tang, Shunshun Wang, Hanjin Cui, Teng Li, and Jiekun Luo. "Deciphering the Therapeutic Mechanisms of Wuzi Ershen Decoction in Treating Oligoasthenozoospermia through the Network Pharmacology Approach." Evidence-Based Complementary and Alternative Medicine 2021 (August 6, 2021): 1–17. http://dx.doi.org/10.1155/2021/5591844.

Full text

Abstract:

Background. Infertility affects approximately 15% of couples around the world, and male factors are accounted for 40–50%. Oligoasthenozoospermia is the most common reason for male infertility. Unfortunately, effective drug therapy is still lacking except for assisted reproductive technology (ART). Previous researchers found that Wuzi Ershen decoction (WZESD) can increase sperm count, enhance sperm vitality, and improve semen quality. However, the pharmacological mechanisms remain unclear. Methods. In this study, we screened compounds and predicted the targets of WZESD based on the TCMSP and BATMAN-TCM database combined with literature searching in the PubMed database. We obtained proteins related to oligoasthenozoospermia through GeneCards and submitted them to STRING to obtain the protein-protein interaction (PPI) network. Potential targets of WZESD were mapped to the network, and the hub targets were screened by topology. We used online platform Metascape and Enrichr for GO and KEGG enrichment analyses. AutoDock Vina was utilized for further verification of the binding mode between compounds and targets. Results. Totally, 276 bioactive compounds were obtained and targeted 681 proteins. 446 oligoasthenozoospermia disease-specific proteins were acquired, and further bioinformatics analysis found that they were mainly involved in the formation of gametes, meiosis, and sperm differentiation. Protein interaction network analysis revealed that target proteins of WZESD were associated with oligoasthenozoospermia disease-specific proteins. The 79 targets of disease-specific proteins, which were anchored by WZESD, mainly participate in the cellular response to the organic cyclic compound, regulation of the apoptotic process, nitricoxide biosynthetic and metabolic process, oxidative stress, and protein phosphorylation regulation, which are the causes for oligoasthenozoospermia. Molecular docking simulation further validated that bioactive compounds originated from WZESD with targeted proteins showed high binding efficiency. Conclusions. This study uncovers the therapeutic mechanisms of WZESD for oligoasthenozoospermia treatment from the perspective of network pharmacology and may provide a valuable reference for further experimental research studies and clinical applications.

APA, Harvard, Vancouver, ISO, and other styles

6

Kutsenko, A. O. "The analysis of the efficiency of the program ІМSI at fertilization in vitro." HEALTH OF WOMAN, no. 6(112) (July 29, 2016): 28–32. http://dx.doi.org/10.15574/hw.2016.112.28.

Full text

Abstract:

The aim of the study: to analyze the results of the program ІМSI as one of the methods of VRT to ensure in vitro fertilization. Materials and methods. The basis of the study consisted of 100 couples with male factor infertility. Pair was examined and treated at the Institute of reproductive medicine (Kiev) in 2013-2015. The Diagnosis verified, assistance was provided in the framework of standard clinical protocols. The 51 men were diagnosed oligoasthenozoospermia, obstructive and non-obstructive azoospermia - in 28 and 21 men, respectively. Results. There were identified features according to the results of cycles. When native - biochemical pregnancy achieved almost equally often oligoasthenozoospermia and obstructive azoospermia (53.0±6.9% and 53.4±9.4%), whereas non-obstructive in two times less (28.6±9.8%). When critical the difference in results is not traced with obstructive and non-obstructive azoospermia and was 16% lower in cases of oligoasthenozoospermia. Biochemical pregnancies occurred in 63 of the 100 pairs (63.0±4.8%), with oligoasthenozoospermia and 37 of 51 (72.5 per cent), obstructive azoospermia – in 19 of 28 (67.8 per cent), non-obstructive – 7 of 21 (33.3 percent). After reproductive losses (5 of 63, 7.9% as) the end result was lower – 58.0±4.9 per cent. The number of births in total in the group with oligoasthenozoospermia was 35 of 51 (68.6%), obstructive and non-obstructive azoospermia - 17 of 28 (60.7 per cent) and 6 of 21 (28.6 per cent), respectively. Conclusion. The data motivate the need of finding opportunities to improve program performance ІМSI. Promising in this regard is the preparation of the pair to her conduct, which goes beyond the limits of the medical, carried out according to the protocols. An important point should be the identification and leveling of risk factors for general medicine and a social plan. Key words: male infertility, the program ІМSI, results.

APA, Harvard, Vancouver, ISO, and other styles

7

Almagor, M. "Spontaneous pregnancies in severe oligoasthenozoospermia." Human Reproduction 16, no. 8 (August 1, 2001): 1780–81. http://dx.doi.org/10.1093/humrep/16.8.1780.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kobori, Yoshitomo, Shigeyuki Ota, Ryo Sato, Hiroshi Yagi, Shigehiro Soh, Gaku Arai, and Hiroshi Okada. "Antioxidant cosupplementation therapy with vitamin C, vitamin E, and coenzyme Q10 in patients with oligoasthenozoospermia." Archivio Italiano di Urologia e Andrologia 86, no. 1 (March 28, 2014): 1. http://dx.doi.org/10.4081/aiua.2014.1.1.

Full text

Abstract:

Objective: Overproduction of reactive oxygen species results in oxidative stress, a deleterious process that damages cell structure as well as lipids, proteins, and DNA. Oxidative stress plays a major role in various human diseases, such as oligoasthenozoospermia syndrome. Materials and methods: We evaluated the effectiveness of antioxidant co-supplementation therapy using vitamin C, vitamin E, and coenzyme Q10 in men with oligoasthenozoospermia. Overall, 169 infertile men with oligoasthenozoospermia received antioxidant therapy with 80 mg/day vitamin C, 40 mg/day vitamin E, and 120 mg/day coenzyme Q10. We evaluated spermiogram parameters at baseline and at 3 and 6 months of follow-up. Results: Significant improvements were evident in sperm concentration and motility following coenzyme Q10 therapy. Treatment resulted in 48 (28.4%) partner pregnancies, of which 16 (9.5%) were spontaneous. Significant improvements in sperm cell concentration and sperm motility were observed after 3 and 6 months of treatment. Conclusions: Vitamin C, vitamin E, and coenzyme Q10 supplementation resulted in a significant improvement in certain semen parameters. However, further studies are needed to empirically determine the effect of supplementation on pregnancy rate.

APA, Harvard, Vancouver, ISO, and other styles

9

Xie, Bao-Guo, Yuan-Hua Huang, Wei-Jie Zhu, and Song Jin. "Comparison of the Outcome of Conventional in vitro Fertilization and Intracytoplasmic Sperm Injection in Moderate Male Infertility from Ejaculate." Urologia Internationalis 94, no. 1 (November 13, 2013): 111–16. http://dx.doi.org/10.1159/000353975.

Full text

Abstract:

Objective: To evaluate whether couples with moderate male infertility should be treated with conventional in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). Patients and Methods: A total of 249 couples with moderate male infertility undergoing their first IVF/ICSI cycle were enrolled in the study. The couples were divided into two groups according to the results of semen analysis: moderate oligozoospermia (O group) and moderate oligoasthenozoospermia (OA group). Sibling oocytes were randomized into groups to be inseminated either by conventional IVF or ICSI. Fertilization rate, embryo quality, implantation rate, and clinical pregnancy rate were examined. Results: There was no difference in the fertilization, implantation, and pregnancy rates between conventional IVF and ICSI in either the O group or OA group (p > 0.05). Additionally, in the OA group, the good quality embryo rate was similar after IVF or ICSI (p > 0.05). However, in the O group, the good quality embryo rate was significantly higher after ICSI than after IVF (p < 0.05). Conclusions: Couples with moderate oligozoospermia or moderate oligoasthenozoospermia did not influence the major indices of IVF. Because of the uncertainties concerning the safety of ICSI, couples with moderate oligozoospermia or moderate oligoasthenozoospermia need not be subjected to this procedure.

APA, Harvard, Vancouver, ISO, and other styles

10

Zhao, Ming Peng, Xiao Shi, Grace Wing Shan Kong, Chi Chiu Wang, Justin Che Yuen Wu, Zhi Xiu Lin, Tin Chiu Li, and David Yiu Leung Chan. "The Therapeutic Effects of a Traditional Chinese Medicine Formula Wuzi Yanzong Pill for the Treatment of Oligoasthenozoospermia: A Meta-Analysis of Randomized Controlled Trials." Evidence-Based Complementary and Alternative Medicine 2018 (January 17, 2018): 1–10. http://dx.doi.org/10.1155/2018/2968025.

Full text

Abstract:

Oligoasthenozoospermia is a crucial factor in male infertility. Wuzi Yanzong (WZYZ) pill is a popular traditional Chinese medicine (TCM) formula which has been used for male infertility treatment for years. However, its effects on semen quality remain controversial. We conducted a preregistered meta-analysis to assess the effect of WZYZ pill for the therapeutic effects on oligoasthenozoospermia. Five randomized controlled trials including 960 participants were selected from databases of domains in North-East Asian regions, PubMed, Embase, and Cochrane Library. WZYZ pill group yielded a greater mean increment on sperm concentration (5 trials: MD 5.99, 95% CI 2.12–9.85, P=0.002), sperm motility (5 trials: MD 4.57, 95% CI 0.47–8.68, P=0.03), sperm morphology (2 trials: MD −1.93, 95% CI −4.87–1.01, P=0.20), activity of acrosomal enzyme (2 trials: MD 28.27, 95% CI 12.41–44.14, P<0.01), volume of semen (2 trials: MD 0.56, 95% CI 0.21–0.91, P=0.002), and a decrement of sperm DNA fragmentation index (2 trials: MD −3.82, 95% CI −6.45–−1.19, P=0.004). However, qualities of selected studies were generally unsatisfactory, and there was inherent heterogeneity among some of the outcomes. Despite these limitations, the WZYZ pill improved sperm quality by improving several semen parameters and decreasing DNA damage in oligoasthenozoospermia patients.

APA, Harvard, Vancouver, ISO, and other styles

11

Karnwal, Shivani. "MANAGEMENT OF MALE INFERTILITY (OLIGOASTHENOZOOSPERMIA) WITH AYURVEDA." International Ayurvedic Medical Journal 8, no. 10 (October 18, 2020): 4902–5. http://dx.doi.org/10.46607/iamj5508102020.

Full text

Abstract:

Male infertility refers to a male’s inability to cause pregnancy in a fertile female. There are many reasons that aid the pathology of male infertility primary includes low sperm count, volume, motility, abnormality in shapes and few reproductive dysfunctions. Oligoasthenozoopsermia which is one of the major causes behind male infertility comprises two conditions – Oligospermia (low sperm count) and Asthenozoo-spermia (reduced motility of sperm).Researches reveals that 1 in every 3 cases of infertility are due to the male partner so nowadays diagnosis and management of both the partners is now considered as a vital tool. In this article, I report a case of a 30-year-old male patient with complaints of wanting an issue after a complete year of regular, unprotected intercourse. For which he had undergone all the regular diagnostic investigations of his wife, which reported no issues and recorded with regular and ovulatory cycles with patent tubes. Then progressing in the diagnosis, he had undergone a semen analysis and got diagnosed with Oligoasthenozoospermia. The issue was successfully treated with Ayurvedic drugs within a period of 1 month.

APA, Harvard, Vancouver, ISO, and other styles

12

KARA, Reyhan, Pelin TAŞDEMİR, Ebru TUNCEZ, Hüseyin GÖRKEMLİ, Duygu DURSUNOĞLU, and Aynur ACAR. "NRF2 mRNA Expression in Ejaculate Spermatozoa from Men with Asthenozoospermia and Oligoasthenozoospermia." Türk Üreme Tıbbı ve Cerrahisi Dergisi 1, no. 2 (2017): 75–81. http://dx.doi.org/10.24074/tjrms.2017-55918.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Fafula, R. V., O. K. Onufrovych, U. P. Iefremova, O. V. Melnyk, I. A. Nakonechnyi, D. Z. Vorobets, and Z. D. Vorobets. "Glutathione content in sperm cells of infertile men." Regulatory Mechanisms in Biosystems 8, no. 2 (April 22, 2017): 157–61. http://dx.doi.org/10.15421/021725.

Full text

Abstract:

Hyperproduction of reactive oxygen species can damage sperm cells and is considered to be one of the mechanisms of male infertility. Cell protection from the damaging effects of free radicals and lipid peroxidation products is generally determined by the degree of antioxidant protection. Glutathione is non-enzymatic antioxidant which plays an important protective role against oxidative damages and lipid peroxidation. The aim of the present work is to determine the content of reduced and oxidized glutathione in sperm cells of infertile men. Semen samples from 20 fertile men (normozoospermics) and 72 infertile patients (12 oligozoospermics, 17 asthenozoospermics, 10 oligoasthenozoospermics and 33 leucocytospermic) were used. The total, oxidized (GSSG) and reduced (GSH) glutathione levels were measured spectrophotometrically. The levels of total glutathione were significantly lower in the spermatozoa of patients with oligozoo-, asthenozoo- and oligoasthenozoospermia than in the control. Infertile groups showed signiﬁcantly decreased values of reduced glutathione in sperm cells vs. fertile men, indicating an alteration of oxidative status. The oxidized glutathione levels in sperm cells of infertile men did not differ from those of normozoospermic men with proven fertility. The GSH/GSSG ratio was signiﬁcantly decreased in the oligo-, astheno- and oligoasthenozoospermic groups compared to the normozoospermic group. In patients with leucocytospermia the GSH/GSSG ratio was lower but these changes were not significant. In addition, glutathione peroxidase activity in sperm cells was decreased in patients with oligozoo-, astenozoo-, oligoastenozoospermia and with leucocytospermia. The most significant changes in glutathione peroxidase activity were observed in infertile men with leucocytospermia. Decreased GSH/GSSG ratio indicates a decline in redox-potential of the glutathione system in sperm cells of men with decreased fertilizing potential. Redistribution between oxidized and reduced forms of glutathione can be caused by depletion of intracellular stores of glutathione and intensification of lipid peroxidation processes. This leads to increased production of reactive oxygen species, further depletion of antioxidant pools and disturbances of structure and function of spermatozoa. Our results indicate that the evaluation of reduced glutathione level and GSH/GSSG ratio in sperm cells of infertile men can be helpful in fertility assessment.

APA, Harvard, Vancouver, ISO, and other styles

14

Rao, Rajdip R., Anup B. Thakar, Nilesh N. Bhatt, Rahul Gandhi, Jayesh Odedra, and Kalpana S. Pate. "Effect of Virechana in the management of Oligoasthenozoospermia (Shukradushti): A Case Report." Journal of Research in Traditional Medicine 2, no. 6 (March 26, 2017): 166–69. http://dx.doi.org/10.21276/jrtm.2017/374.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Vendrell, J. M., F. Garcia, A. Veiga, G. Calderon, S. Egozcue, J. Egozcue, and P. N. Barri. "Meiotic abnormalities and spermatogenic parameters in severe oligoasthenozoospermia." Human Reproduction 14, no. 2 (February 1, 1999): 375–78. http://dx.doi.org/10.1093/humrep/14.2.375.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Silber, SJ. "A modern view of male infertility." Reproduction, Fertility and Development 6, no. 1 (1994): 93. http://dx.doi.org/10.1071/rd9940093.

Full text

Abstract:

It is archaic to view male factor infertility today separately from in vitro fertilization (IVF) and treatment of the female partner. Oligoasthenozoospermia may be an inherited condition (most likely on the Y chromosome), and is refractory to any treatment of the male including hormones and varicocelectomy. IVF technology is the only justifiable approach for achieving a pregnancy in these couples. The reasons for this view and the suggested modern approach to couples with oligoasthenozoospermia are outlined in this review. However, obstructive azoospermia is different as it can be successfully corrected with microsurgery in over 90% of men. When it cannot be corrected, as in congenital absence of vas, microsurgical sperm retrieval combined with IVF can still be highly effective in producing pregnancy with sperm from the husband. The most important arena for research into male infertility in the next decade will be to map out the deletions on the Y chromosome that might result in defective spermatogenesis, and which probably cause most cases of non-obstructive male factor infertility.

APA, Harvard, Vancouver, ISO, and other styles

17

Gholami, Delnya, Hamideh Jafari-Ghahfarokhi, Maryam Nemati-Dehkordi, and Hossien Teimori. "Y chromosome microdeletions frequency in idiopathic azoospermia, oligoasthenozoospermia, and oligospermia." International Journal of Reproductive BioMedicine 15, no. 11 (November 1, 2017): 703–12. http://dx.doi.org/10.29252/ijrm.15.11.703.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Scaglia, H. E., C. M. Timossi, C. A. Carrere, C. Zylbersztein, M. E. Colombani, G. Rey-Valzacchi, and D. R. Aquilano. "Altered luteinizing hormone pulsatility in infertile patients with idiopathic oligoasthenozoospermia." Human Reproduction 13, no. 10 (October 1, 1998): 2782–86. http://dx.doi.org/10.1093/humrep/13.10.2782.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Shurygina, O. V., L. A. Belyaeva, D. Yu Rusakov, S. N. Yukhimets, N. V. Ratenkova, and O. V. Popova. "ASSESSMENT OF OXIDATIVE STRESS IN MEN WITH NORMOZOOSPERMIA AND OLIGOASTHENOZOOSPERMIA." Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH), no. 5 (February 28, 2021): 84–90. http://dx.doi.org/10.20340/vmi-rvz.2020.5.9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Saeed, Husamuldeen Salim Mohammed. "Using Zinc in Management of Subfertile Male Patients: a Clinical Trial." AL-Kindy College Medical Journal 13, no. 1 (October 31, 2019): 32–38. http://dx.doi.org/10.47723/kcmj.v13i1.120.

Full text

Abstract:

Background: The use of minerals in treatment of different diseases is as old as man himself. zinc is the most famous trace mineral related to male sexual function. Oligoasthenozoospermic subfertile patients were treated with zinc sulphate for three months. Objectives: Aim of the research is to investigate the role of Zinc and if it affects the abnormalities of some semen parameters and to study the possible role of pharmaceutical preperations of zinc in amelioration of male subfertility as well as to assess the ability of Zinc to induce changes in the serum and semen zinc levels in addition to the levels of reproductive hormones (FSH and Testosterone). Type of the study: The study is a single group pretest-posttest experimental prospective comparative self-control; clinical trial research. Methods: The patients were tested before and after the treatment for semen analysis via Computerized Assisted Semen Analysis (CASA) dynamic analysis report I and II as well as for FSH and Testosterone hormonal levels, serum and semen zinc levels . Results: Zinc administration induced a significant increase(p≤0.001) in FSH, Testosterone, serum and semen zinc level as well as in the total and progressive sperm motility percentages . Conclusions: Zinc administration induced significant changes (p≤0.001) towards improvement in the total and progressive sperm motility percentages in oligoasthenozoospermic patients by CASA dynamic analysis report I and II.

APA, Harvard, Vancouver, ISO, and other styles

21

Ahmed, Marwa, and Dalia Abd El-Aziz. "The Relations between Cadmium, Zinc and Oxidative stress in Oligoasthenozoospermic Men." Bulletin of Egyptian Society for Physiological Sciences 29, no. 1 (June 1, 2009): 245–58. http://dx.doi.org/10.21608/besps.2009.36344.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Awad, Ahmed A., Osama M. Selim, Yasser I. Elkhiat, Mohamed S. Abdallah, and Rania S. Elkady. "Prevalence of Chlamydia trachomatis asymptomatic urethritis among infertile men with oligoasthenozoospermia." Human Andrology 1, no. 3 (December 2011): 79–82. http://dx.doi.org/10.1097/01.xha.0000407145.38519.71.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Roaiah, M. M. F., T. Mostafa, D. Salem, A. R. El-Nashar, I. I. Kamel, and M. S. El-Kashlan. "?-1,4-Glucosidase activity in infertile oligoasthenozoospermic men with and without varicocele." Andrologia 39, no. 1 (February 2007): 28–32. http://dx.doi.org/10.1111/j.1439-0272.2006.00756.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Matalliotakis, I., A. Evangeliou, S. Sifakis, A. Zolindaki, M. Neonaki, and E. Koumantakis. "R-014. Seminal carintine concentrations in normal, oligoasthenozoospermic and azoospermic patients." Human Reproduction 12, Suppl_2 (June 1997): 242–43. http://dx.doi.org/10.1093/humrep/12.suppl_2.242-b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Alahmar, Ahmed T. "Effect of Vitamin C, Vitamin E, Zinc, Selenium, and Coenzyme Q10 in Infertile Men with Idiopathic Oligoasthenozoospermia." International Journal of Infertility & Fetal Medicine 8, no. 2 (August 2017): 45–49. http://dx.doi.org/10.5005/jp-journals-10016-1147.

Full text

Abstract:

ABSTRACT Introduction Accumulating evidence suggests that oxidative stress plays an important role in the development of male infertility and recently antioxidants have been tried to treat men with idiopathic infertility. Objective To assess the effect of treatment with vitamin C, vitamin E, zinc, selenium, and coenzyme Q10 on seminal fluid parameters in infertile men with idiopathic oligoasthenozoospermia. Materials and methods A prospective randomized trial was conducted on 32 infertile men with idiopathic oligoasthenozoospmia who received a daily supplement of one caplet containing vitamin C (90 mg/day), vitamin E (15 mg/day), coenzyme Q10 (4 mg/day), selenium (30 µg/day), and zinc (5 mg/day) for 3 months. Semen analysis was performed at baseline and 3 months after treatment using World Health Organization (WHO) 2010 guidelines. Results Significant improvement in sperm concentration was observed after combination therapy (9.13 ± 4.29 vs 11.3 ± 6.05 × 106/mL, p < 0.05). Sperm progressive motility (18.1 ± 8.68 vs 24.6 ± 10.2%, p < 0.01) and total motility (28.4 ± 8.71 vs 34.4 ± 11.7%, p < 0.01) also increased significantly following treatment. No change, however, was observed in semen volume or the proportion of sperms with normal morphology. Conclusion The combination of vitamin C, vitamin E, zinc, selenium, and coenzyme Q10 can significantly improve sperm concentration and motility in infertile men with idiopathic oligoasthenozoospermia, which could be attributed to their synergistic antioxidant action. How to cite this article Alahmar AT. Effect of Vitamin C, Vitamin E, Zinc, Selenium, and Coenzyme Q10 in Infertile Men with Idiopathic Oligoasthenozoospermia. Int J Infertil Fetal Med 2017;8(2):45-49.

APA, Harvard, Vancouver, ISO, and other styles

26

Sosnin, D. Yu Sosnin, N. A. Zubareva Zubareva, O. Yu Nenasheva Nenasheva, A. V. Krivtsov Krivtsov, N. V. Karimova Karimova, and N. V. Pozdin Pozdin. "Ejaculate and serum procalcitonin levels in healthy men and men with oligoasthenozoospermia." Urologiia 1_2017 (April 5, 2017): 61–65. http://dx.doi.org/10.18565/urol.2017.1.61-65.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Giacomini, Elisa, Blendi Ura, Elena Giolo, Stefania Luppi, Monica Martinelli, Rodolfo C. Garcia, and Giuseppe Ricci. "Comparative analysis of the seminal plasma proteomes of oligoasthenozoospermic and normozoospermic men." Reproductive BioMedicine Online 30, no. 5 (May 2015): 522–31. http://dx.doi.org/10.1016/j.rbmo.2015.01.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Raaia, Mohamed F., Ahmed A. Atyeah, Yasser I. Elkhiat, and Hossam G. Elenany. "Treatment of idiopathic asthenozoospermia, either isolated or oligoasthenozoospermia, with α-lipoic acid." Human Andrology 2, no. 4 (December 2012): 94–98. http://dx.doi.org/10.1097/01.xha.0000419798.52349.2e.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Vučić, N. L. J., Z. Z. Nikolić, V. D. Vukotić, S. M. Tomović, I. I. Vuković, S. D. Kanazir, D. L. J. Savić-Pavićević, and G. N. Brajušković. "NOS3 gene variants and male infertility: Association of 4a/4b with oligoasthenozoospermia." Andrologia 50, no. 1 (May 3, 2017): e12817. http://dx.doi.org/10.1111/and.12817.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Liu, Yanyan, Hongmei Zhu, Xuan Zhang, Ting Hu, Zhu Zhang, Jing Wang, Yi Lai, et al. "Infertility in a man with oligoasthenozoospermia associated with mosaic chromosome 22q11 deletion." Molecular Genetics & Genomic Medicine 6, no. 6 (November 2018): 1249–54. http://dx.doi.org/10.1002/mgg3.487.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Maier, Ulrich, and Gregor Hienert. "Tamoxifen and Kallikrein in Therapy of Oligoasthenozoospermia: Results of a Randomized Study." European Urology 17, no. 3 (1990): 223–25. http://dx.doi.org/10.1159/000464043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Isidor, Bertrand, Carmen Capito, Françoise Paris, Sabine Baron, Nadège Corradini, Blandine Cabaret, Marc-David Leclair, et al. "Familial Frameshift SRY Mutation Inherited from a Mosaic Father with Testicular Dysgenesis Syndrome." Journal of Clinical Endocrinology & Metabolism 94, no. 9 (September 1, 2009): 3467–71. http://dx.doi.org/10.1210/jc.2009-0226.

Full text

Abstract:

Context: The SRY gene encodes a transcription factor responsible for initiating testis differentiation. Mutations in SRY almost always result in XY sex reversal with pure gonadal dysgenesis and an increased risk of gonadal tumor. Most of these mutations are de novo, affecting only one individual in a family. Only a small subset of mutations is shared between a phenotypically normal father and one or more of his affected children. Incomplete penetrance and somatic mosaicism are two hypotheses that may explain a normal phenotype in a father carrying a SRY mutation. Patients and Results: We describe a family with two sisters with XY sex reversal and pure gonadal dysgenesis and a phenotypically normal brother. A novel constitutional frameshift SRY mutation was identified in both sisters and was absent in the brother. The single base pair deletion (c.71delA) led to a premature stop codon in position 60 of the protein, removing entirely the high-mobility group domain and the DNA-binding domain of SRY. The father of the three children presented with hypospadias; cryptorchidism; testicular seminoma and oligoasthenozoospermia, an association termed testicular dysgenesis syndrome (TDS); and the SRY mutation in a mosaic state in the peripheral blood and the tumor. Conclusions: This observation of somatic and germinal mosaicism for a SRY mutation may explain the variable penetrance in some familial gonadal dysgenesis. Importantly, the present report is the first one describing the association of SRY mutation in a male with TDS. This suggests that mutations in a sex-determining gene may contribute to the pathogenesis of TDS. A fertile man is described with hypospadias, cryptorchidism, testicular seminoma, and oligoasthenozoospermia, and a mosaic SRY mutation.

APA, Harvard, Vancouver, ISO, and other styles

33

Skandhan, KP, BN Mazumdar, and B. Sumangala. "Study into the Iron Content of Seminal Plasma in Normal and Infertile Subjects." Urologia Journal 79, no. 1 (January 2012): 54–57. http://dx.doi.org/10.5301/ru.2012.9023.

Full text

Abstract:

The iron content in seminal plasma of normal (n19), oligozoospermic (n11), azoospermic (n12), oligoasthenozoospermic (n19), and asthenozoospermic (n17) subjects was estimated by using atomic absorption spectrophotometer. The concentration of iron in normal seminal plasma varied from 265 to 365 mg%. The source of iron in seminal plasma seems to be the adnexal glands and not spermatozoa, as azoospermic semen also contained it. A statistically highly significant difference was seen when normal was compared with azoospermia and with asthenozoospermia. The necessary average wastage of iron through semen is calculated as 2.52 mg/day. This value is highly variable according to the seminal volume and frequency of ejaculation.

APA, Harvard, Vancouver, ISO, and other styles

34

Lepej, Snježana Židovec, Sanja Vujisić, Feodora Stipoljev, and Renata Mažuran. "Interferon-α-like biological activity in human seminal plasma, follicular fluid, embryo culture medium, amniotic fluid and fetal blood." Reproduction, Fertility and Development 15, no. 8 (2003): 423. http://dx.doi.org/10.1071/rd03020.

Full text

Abstract:

Interferons (IFNs) are a group of cytokines exhibiting antiviral, antiproliferative and immunoregulatory properties. The principal stimulus for the synthesis of IFNs is the presence of viral double-stranded RNA, although rare examples of constitutive synthesis have also been described. The aim of the present study was to determine IFN-α-like biological activity in the seminal plasma, follicular and amniotic fluid, embryo culture medium, and fetal blood obtained from patients without apparent viral or bacterial infections. Interferon-α-like biological activity was determined by a standard cytopathic effect inhibition bioassay. The study included two groups of patients. The first group consisted of 30 married couples participating in the programme for assisted reproduction and the second group consisted of 23 patients scheduled for prenatal diagnosis (15 for amniocentesis and eight for cordocentesis). The seminal plasma of infertile men (asthenozoospermia, oligoasthenozoospermia) contained a high titre of IFN-α-like antiviral activity. Asthenozoospermia was diagnosed in men with a normal sperm concentration but less than 50% progressively motile sperm and oligoasthenozoospermia was diagnosed in men with a sperm count less than 1 × 106 mL−1. Despite slightly higher antiviral titres in the seminal plasma obtained from asthenozoospermic patients, no clear association between IFN-α-like biological activity and sperm concentration was found. Interferon-α-like biological activity was found in all samples of follicular and amniotic fluid and in fetal blood of patients with intrauterine growth retardation and trisomy 18. Antiviral titres from seminal plasma and follicular fluids were significantly higher compared with amniotic fluids and fetal blood. Embryo culture medium did not contain IFN-α-like biological activity. Our results demonstrate that IFN-α-like activity in biological fluids is relevant for reproduction, even in the absence of infection.

APA, Harvard, Vancouver, ISO, and other styles

35

Taha, Emad A., Sohair K. Sayed, Nagwa M. Ghandour, Ali M. Mahran, Medhat A. Saleh, Magdy M. Amin, and Rany Shamloul. "Correlation between seminal lead and cadmium and seminal parameters in idiopathic oligoasthenozoospermic males." Central European Journal of Urology 65 (2013): 84–92. http://dx.doi.org/10.5173/ceju.2013.01.art28.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Yazicioglu, Gozde, Özcan Budak, Ahmet Yigit Cakiroglu, Emek Doger, Sebiha Ozdemir Ozkan, and Serdar Filiz. "The association between male age and fertilization/pregnancies rate in severely oligoasthenozoospermic patients." Reproductive BioMedicine Online 28 (May 2014): S23—S24. http://dx.doi.org/10.1016/s1472-6483(14)50055-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Zhu, Feng, Peipei Yan, Jingjing Zhang, Yiqiang Cui, Meimei Zheng, Yiwei Cheng, Yueshuai Guo, Xiaoyu Yang, Xuejiang Guo, and Hui Zhu. "Deficiency of TPPP2, a factor linked to oligoasthenozoospermia, causes subfertility in male mice." Journal of Cellular and Molecular Medicine 23, no. 4 (January 24, 2019): 2583–94. http://dx.doi.org/10.1111/jcmm.14149.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Rani, Deepa Selvi, S. Justin Carlus, J. Poongothai, Amara Jyothi, Kadupa Pavani, Nalini J. Gupta, Alla G. Reddy, et al. "CAG repeat variation in the mtDNA polymerase γ is not associated with oligoasthenozoospermia." International Journal of Andrology 32, no. 6 (September 16, 2008): 647–55. http://dx.doi.org/10.1111/j.1365-2605.2008.00919.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Hibi, H., K. Kato, K. Mitsui, T. Taki, Y. Yamada, N. Honda, H. Fukatsu, and M. Yamamoto. "Treatment of Oligoasthenozoospermia with Tranilast, a Mast Cell Blocker, After Long-Term Administration." Archives of Andrology 48, no. 6 (January 2002): 451–59. http://dx.doi.org/10.1080/01485010290099200.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Frühmesser, Anne, Peter H. Vogt, Jutta Zimmer, Martina Witsch-Baumgartner, Christine Fauth, Johannes Zschocke, Germar-Michael Pinggera, and Dieter Kotzot. "Single nucleotide polymorphism array analysis in men with idiopathic azoospermia or oligoasthenozoospermia syndrome." Fertility and Sterility 100, no. 1 (July 2013): 81–87. http://dx.doi.org/10.1016/j.fertnstert.2013.03.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Kardoust Parizi, Mehdi, and Nasser Shakhssalim. "Management of Zinner’s Syndrome Associated with Contralateral Seminal Vesicle Hypoplasia: A Case Report." Case Reports in Urology 2013 (2013): 1–3. http://dx.doi.org/10.1155/2013/494215.

Full text

Abstract:

A 27-year-old man presented with chronic hematospermia, painful ejaculation, and primary infertility. Physical examination, transrectal ultrasonography, and pelvic magnetic resonance imaging (MRI) demonstrated left seminal vesicle cyst, left renal agenesia, and contralateral seminal vesicle hypoplasia. Hormone workup (LH, FSH, prolactin, and testosterone) was normal. Sperm analysis showed oligoasthenozoospermia and low ejaculate volume. We performed transurethral resection of the ejaculatory duct (TUR-ED) using methylene blue vasography guidance without surgical-related complications. Hematospermia and painful ejaculation completely improved at 2-month followup, and the patient’s wife experienced a missed abortion thereafter. This patient was considered as a rare variant of Zinner’s syndrome and was managed effectively with a less invasive treatment modality (TUR-ED).

APA, Harvard, Vancouver, ISO, and other styles

42

Liu, Xin, Wenting Wang, Peng Zhu, Jiahui Wang, Yanwei Wang, Xuebo Wang, Juan Liu, et al. "In-depth quantitative proteome analysis of seminal plasma from men with oligoasthenozoospermia and normozoospermia." Reproductive BioMedicine Online 37, no. 4 (October 2018): 467–79. http://dx.doi.org/10.1016/j.rbmo.2018.06.025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Amory, J. K., K. A. Ostrowski, J. R. Gannon, K. Berkseth, F. Stevison, N. Isoherranen, C. H. Muller, and T. Walsh. "Isotretinoin administration improves sperm production in men with infertility from oligoasthenozoospermia: a pilot study." Andrology 5, no. 6 (October 5, 2017): 1115–23. http://dx.doi.org/10.1111/andr.12420.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Ragni, G., G. C. Lombroso Finzi, A. Caccamo, A. Dalla Serra, and P. G. Crosignani. "Enhanced quality of capacitated spermatozoa from oligoasthenozoospermic men after incubation in test yolk medium." Andrologia 25, no. 6 (April 24, 2009): 337–39. http://dx.doi.org/10.1111/j.1439-0272.1993.tb02738.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Shuai, H. L., Q. Ye, Y. H. Huang, and B. G. Xie. "Comparison of conventionalin vitrofertilisation and intracytoplasmic sperm injection outcomes in patients with moderate oligoasthenozoospermia." Andrologia 47, no. 5 (May 9, 2014): 499–504. http://dx.doi.org/10.1111/and.12291.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Skandhan, Kalanghot P., Birendranath Mazumdar, Balakrishnan Sumangala, and Vasudevan Jaya. "Seminal Plasma Calcium in Normal and Infertile Patients." Urologia Journal 84, no. 1 (July 9, 2016): 35–37. http://dx.doi.org/10.5301/uro.5000167.

Full text

Abstract:

Introduction In this study an attempt is made to find out the level of calcium in seminal plasma of normal and infertile patients. Materials and Methods Semen samples are collected from 34 normal men and 112 infertile patients. After semen evaluation seminal plasma was separated and calcium level was measured in it. Results Calcium level in mg% is recorded in each group as follows; in normozospermia (n34) 20.14 ± 1.25 (±SE), oligozoospermia (n26) 9.76 ± 1.17, azoospermia (n33) 14.65 ± 2.63, oligoasthenozoosperma (n28) 20.91 ± 1.94 and in asthenozoospermia (n25) 11.56 ± 1.68. Statistically highly significant reduction in calcium is seen in Oligozoospermia and asthenozoospermia. Conclusions The probable reasons for these two conditions are discussed.

APA, Harvard, Vancouver, ISO, and other styles

47

Sanchez, R., V. Isachenko, A. M. Petrunkina, J. Risopatron, M. Schulz, and E. Isachenko. "Live Birth After Intrauterine Insemination With Spermatozoa From an Oligoasthenozoospermic Patient Vitrified Without Permeable Cryoprotectants." Journal of Andrology 33, no. 4 (August 25, 2011): 559–62. http://dx.doi.org/10.2164/jandrol.111.014274.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Zou, Tiejun, Xiang Liu, Shangshu Ding, and Junping Xing. "Evaluation of sperm mitochondrial function using rh123/PI dual fluorescent staining in asthenospermia and oligoasthenozoospermia." Journal of Biomedical Research 24, no. 5 (September 2010): 404–10. http://dx.doi.org/10.1016/s1674-8301(10)60054-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Jia, Chunshu, Linlin Li, Shuang Chen, Dejun Li, Xuan Wang, Ruizhi Liu, and Hongguo Zhang. "Cytogenetic and molecular characterization of an oligoasthenozoospermia male carrier of an unbalanced Y;22 translocation." Medicine 98, no. 15 (April 2019): e15209. http://dx.doi.org/10.1097/md.0000000000015209.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Diaconu, M., Y. Tangat, D. Bohm, H. Kuhn, H. W. Michelmann, G. Schreiber, G. Haidl, H.-J. Glander, W. Engel, and K. Nayernia. "Failure of phospholipid hydroperoxide glutathione peroxidase expression in oligoasthenozoospermia and mutations in the PHGPx gene." Andrologia 38, no. 4 (August 2006): 152–57. http://dx.doi.org/10.1111/j.1439-0272.2006.00729.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!